Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited

 
• By Alaric DeArment
European regulators recommended Oxbryta be suspended while a data review is ongoing. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet